Literature DB >> 3128354

Hemostatic effect of a heat-treated factor VIII concentrate (Haemate P) in von Willebrand's disease.

H Fukui1, M Nishino, S Terada, T Nishikubo, A Yoshioka, S Kinoshita, K Niinomi, K Yoshioka.   

Abstract

A heat-treated factor VIII (F VIII) concentrate (Haemate P) has been administered to patients with various types of von Willebrand's disease (vWD). The 4 activities of F VIII/vWF as well as change in the multimeric structure of vWF were then studied. In 4 patients with type I vWF who were given a Ristocetin cofactor (Rcof) dose of 42-78 U/kg, there was a clear reduction of the bleeding time and an increase of F VIII: C, F VIII: Ag, Rcof and vWF: Ag for several hours. The recovery of Rcof. after 1 h was 50-75%. Although the multimeric composition of vWF in these patients was similar to that of normal plasma, the density of each multimer band was very low. After infusion, however, the density of all multimer bands increased for several hours, to decrease again after 24 h. In 4 patients with type II A vWD who received a dose of Rcof of 55-76 U/kg, the 4 activities of F VIII/vWF increased similarly as was the case in type I. All patients had only 3-4 smaller multimer bands. New larger and intermediate multimers appeared for several hours after infusion of the preparation. Two patients with type III vWD who received doses of Rcof of 52 and 65 U/kg showed also a similar increase in the 4 activities of F VIII/vWF after infusion. All the multimers lacking in these patients appeared for several hours after infusion.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3128354     DOI: 10.1007/bf00320748

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  12 in total

1.  Failure of AHF concentration to control bleeding in von Willebrand's disease.

Authors:  D Green; E V Potter
Journal:  Am J Med       Date:  1976-03       Impact factor: 4.965

2.  A one-stage factor VIII (antihaemophilic globulin) assay and its use on venous and capillary plasma.

Authors:  R M HARDISTY; J C MACPHERSON
Journal:  Thromb Diath Haemorrh       Date:  1962-05-15

3.  Characteristics of various factor VIII concentrates used in treatment of haemophilia A.

Authors:  I M Nilsson; U Hedner
Journal:  Br J Haematol       Date:  1977-12       Impact factor: 6.998

4.  The case for heat-treated products.

Authors:  J P Allain; P L Masson; R E Dolkart
Journal:  Lancet       Date:  1985-04-06       Impact factor: 79.321

5.  Inability of pasteurised factor VIII preparations to induce antibodies to HTLV-III after long-term treatment.

Authors:  J Mösseler; K Schimpf; G Auerswald; H Bayer; J Schneider; G Hunsmann
Journal:  Lancet       Date:  1985-05-11       Impact factor: 79.321

6.  The use of heat-treated Factor VIII-concentrates in von Willebrand's disease.

Authors:  M Köhler; P Hellstern; E Wenzel
Journal:  Blut       Date:  1985-01

7.  In vitro characterization of various factor VIII concentrates.

Authors:  A Yoshioka; M Shima; M Nishino; N Yoshikawa; H Fukui
Journal:  Arzneimittelforschung       Date:  1987-07

8.  Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.

Authors:  C B Laurell
Journal:  Anal Biochem       Date:  1966-04       Impact factor: 3.365

9.  An immunoradiometric assay for procoagulant factor VIII antigen: results in haemophilia, von Willebrand's disease and fetal plasma and serum.

Authors:  I R Peake; A L Bloom; J C Giddings; C A Ludlam
Journal:  Br J Haematol       Date:  1979-06       Impact factor: 6.998

10.  The complex multimeric composition of factor VIII/von Willebrand factor.

Authors:  Z M Ruggeri; T S Zimmerman
Journal:  Blood       Date:  1981-06       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.